What is Paradromics?
Paradromics is at the forefront of the neuro-engineering industry, specializing in high-resolution brain activity recording and artificial intelligence-driven data interpretation. The company's flagship platform, Connexus, is designed to provide a voice to individuals suffering from severe paralysis, while its secondary initiative, Tempo, targets mental health through sophisticated brain-state monitoring. By bridging the gap between neurological data and actionable health insights, Paradromics addresses critical unmet needs for patients with conditions such as ALS, stroke, and spinal cord injuries. The firm operates at the intersection of deep tech and medical diagnostics, leveraging scalable hardware to redefine the standard of care in neuro-restoration.
How much funding has Paradromics raised?
Paradromics has raised a total of $61.3M across 5 funding rounds:
Debt
$985K
Angel/Seed
$7M
Debt
$350K
Angel/Seed
$20M
Other Financing Round
$33M
Debt (2015): $985K, investors not publicly disclosed
Angel/Seed (2018): $7M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Angel/Seed (2021): $20M featuring Dolby Family Ventures, Alpha Edison, IT Farm, Synergy Ventures, Westcott, Prime Movers Lab, and Pureland Group
Other Financing Round (2023): $33M backed by Dolby Family Ventures, Westcott, and Green Sands Equity
Key Investors in Paradromics
Dolby Family Ventures
A venture firm focused on early-stage science and engineering challenges, with a specific mandate for precision neuroscience and life sciences platforms.
Green Sands Equity
A boutique private equity firm specializing in growth equity for technology and healthcare, bridging the gap between private innovation and government policy.
Prime Movers Lab
A venture capital firm dedicated to funding breakthrough scientific startups that aim to transform industries and improve human longevity.
What's next for Paradromics?
With the latest injection of capital, Paradromics is poised to scale its clinical trial operations and refine its AI-driven neural decoding algorithms. The strategic focus will likely shift toward regulatory milestones and the expansion of its manufacturing capabilities to support the rollout of the Connexus system. As the company matures, it will continue to leverage its high-profile investor base to navigate the complex landscape of medical device approval and global market entry, ensuring that its neurotechnology solutions reach the patients who need them most while maintaining a competitive edge in the rapidly evolving BCI market.
See full Paradromics company page
